Anti-TNF and skin inflammation in IBD: A new paradox in gastroenterology?

Gut

Volumn 63, Issue 4, 2014, Pages 533-535

  Niess, Jan Hendrik ^a   Danese, Silvio ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; USTEKINUMAB;

CROHN DISEASE; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG SUBSTITUTION; ECZEMA; HUMAN; INFLAMMATORY BOWEL DISEASE; NOTE; PARADOXICAL DRUG REACTION; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SKIN DEFECT; SPONDYLARTHRITIS; XEROSIS;

INFLAMMATORY BOWEL DISEASE; TNF;

ANTIBODIES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKINS; MALE; PSORIASIS; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84895501093     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-304683     Document Type: Note

References (17)

1. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79.
2. Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:644-59.
3. Massara A, Cavazzini L, La Corte R, et al. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum 2010;39:313-19.
4. Clementine RR, Lyman J, Zakem J, et al. Tumor necrosis factor-alpha antagonist-induced sarcoidosis. J Clin Rheumatol 2010;16:274-9.
5. Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59:996-1001. (Pubitemid 351990997)
6. Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010;8:1048-55.
7. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007;86:242-51. (Pubitemid 47067483)
8. Watson AJ. In vivo single-photon emission computed tomography imaging of apoptosis in Crohn's disease and anti-tumour necrosis factor therapy. Gut 2007;56:461-3. (Pubitemid 46580497)
9. Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22- expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014;63:567-77.
10. Wojtal KA, Rogler G, Scharl M, et al. Fc gamma receptor CD64 modulates the inhibitory activity of infliximab. PLoS ONE 2012;7:e43361.
11. Radulovic K, Manta C, Rossini V, et al. CD69 regulates type I IFN-induced tolerogenic signals to mucosal CD4T cells that attenuate their colitogenic potential. J Immunol 2012;188:2001-13.
12. Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010;16:406-12.
13. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nature reviews. Gastroenterol Hepatol 2012;9:496-503.
14. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011;140:1756-67.
15. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61:1693-700.
16. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190-9.
17. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012;367:1519-28.